Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 1
1978 2
1980 1
1982 1
1985 1
1987 1
1992 1
1994 2
1996 1
1997 1
1999 1
2000 2
2001 1
2004 1
2008 1
2009 1
2010 2
2011 3
2012 7
2013 1
2014 1
2015 4
2016 6
2017 2
2018 9
2019 5
2020 2
2021 3
2022 4
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Traitement par CAR-T des leucémies aiguës de l'adulte.
Rahal I, Cabannes-Hamy A, Boissel N. Rahal I, et al. Bull Cancer. 2018 Dec;105 Suppl 2:S158-S167. doi: 10.1016/S0007-4551(19)30046-3. Bull Cancer. 2018. PMID: 30686354 Review. French.
The prognosis for acute lymphoblastic leukemia (ALL) in adults remains poor in refractory or relapsed (R/R) situations. Among the immunotherapy strategies that have recently been developed, CAR-T cells (chimeric antigen receptor modified T-cells) represent a major t …
The prognosis for acute lymphoblastic leukemia (ALL) in adults remains poor in refractory or relapsed (R/R) situations. Among …
Resistance Training, Fatigue, Quality of Life, Anxiety in Breast Cancer Survivors.
Moraes RF, Ferreira-Júnior JB, Marques VA, Vieira A, Lira CAB, Campos MH, Freitas-Junior R, Rahal RMS, Gentil P, Vieira CA. Moraes RF, et al. J Strength Cond Res. 2021 May 1;35(5):1350-1356. doi: 10.1519/JSC.0000000000003817. J Strength Cond Res. 2021. PMID: 33677463
Moraes, RF, Ferreira-Junior, JB, Marques, VA, Vieira, A, Lira, CAB, Campos, MH, Freitas-Junior, R, Rahal, RMS, Gentil, P, and Vieira, CA. Resistance training, fatigue, quality of life, anxiety in breast cancer survivors. ...
Moraes, RF, Ferreira-Junior, JB, Marques, VA, Vieira, A, Lira, CAB, Campos, MH, Freitas-Junior, R, Rahal, RMS, Gentil, P, and …
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
Curado F, Rösner S, Zielke S, Westphal G, Grittner U, Skrahina V, Alasel M, Malik AM, Beetz C, Böttcher T, Barel G, Sah AP, Dinur T, Anjum N, Ichraf Q, Kriouile Y, Hadipour Z, Hadipour F, Revel-Vilk S, Cozma C, Hartkamp J, Cheema H, Zimran A, Bauer P, Rolfs A; LYSO-PROOF Study Group. Curado F, et al. Diagnostics (Basel). 2023 Aug 30;13(17):2812. doi: 10.3390/diagnostics13172812. Diagnostics (Basel). 2023. PMID: 37685353 Free PMC article.

Though lyso-Gb1 values at enrollment were widely distributed, they displayed a moderate and statistically highly significant correlation with disease severity measured by the GD-DS3 scoring system in all GD patients (r = 0.602, p < 0.0001). These findings support the ut

Though lyso-Gb1 values at enrollment were widely distributed, they displayed a moderate and statistically highly significant correlation wit …
The Psychological Science Accelerator's COVID-19 rapid-response dataset.
Buchanan EM, Lewis SC, Paris B, Forscher PS, Pavlacic JM, Beshears JE, Drexler SM, Gourdon-Kanhukamwe A, Mallik PR, Silan MAA, Miller JK, IJzerman H, Moshontz H, Beaudry JL, Suchow JW, Chartier CR, Coles NA, Sharifian M, Todsen AL, Levitan CA, Azevedo F, Legate N, Heller B, Rothman AJ, Dorison CA, Gill BP, Wang K, Rees VW, Gibbs N, Goldenberg A, Thi Nguyen TV, Gross JJ, Kaminski G, von Bastian CC, Paruzel-Czachura M, Mosannenzadeh F, Azouaghe S, Bran A, Ruiz-Fernandez S, Santos AC, Reggev N, Zickfeld JH, Akkas H, Pantazi M, Ropovik I, Korbmacher M, Arriaga P, Gjoneska B, Warmelink L, Alves SG, de Holanda Coelho GL, Stieger S, Schei V, Hanel PHP, Szaszi B, Fedotov M, Antfolk J, Marcu GM, Schrötter J, Kunst JR, Geiger SJ, Adetula A, Kocalar HE, Kielińska J, Kačmár P, Bokkour A, Galindo-Caballero OJ, Djamai I, Pöntinen SJ, Agesin BE, Jernsäther T, Urooj A, Rachev NR, Koptjevskaja-Tamm M, Kurfalı M, Pit IL, Li R, Çoksan S, Dubrov D, Paltrow TE, Baník G, Korobova T, Studzinska A, Jiang X, Aruta JJBR, Vintr J, Chiu F, Kaliska L, Berkessel JB, Tümer M, Morales-Izquierdo S, Chuan-Peng H, Vezirian K, Rosa AD, Bialobrzeska O, Vasilev MR, Beitner J, Kácha O, Žuro B, Westerlund M, Nedelcheva-… See abstract for full author list ➔ Buchanan EM, et al. Sci Data. 2023 Feb 11;10(1):87. doi: 10.1038/s41597-022-01811-7. Sci Data. 2023. PMID: 36774440 Free PMC article.
Natural Products Isolated from Oriental Medicinal Herbs Inactivate Zika Virus.
Batista MN, Braga ACS, Campos GRF, Souza MM, Matos RPA, Lopes TZ, Candido NM, Lima MLD, Machado FC, Andrade STQ, Bittar C, Nogueira ML, Carneiro BM, Mariutti RB, Arni RK, Calmon MF, Rahal P. Batista MN, et al. Viruses. 2019 Jan 11;11(1):49. doi: 10.3390/v11010049. Viruses. 2019. PMID: 30641880 Free PMC article.
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Pett SL, et al. HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13. HIV Med. 2018. PMID: 28703491 Free article. Clinical Trial.
OBJECTIVES: The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor-5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir-boosted protease inhibitor (PI/r) component of a two nucleos(t)ide reverse transcriptase inhi …
OBJECTIVES: The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor-5 (CCR5) inhibitor, was a safe …
74 results